StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
TG Therapeutics (TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI
August 1, 2023 7:28 AM
TG Therapeutics (NASDAQ ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Momentum Movers
Next Articles
Goldman Sachs Upgrades TG Therapeutics (TGTX) to Neutral, 'Valuation reflects Briumvi outlook'
August 2, 2023 7:09 AM
TG Therapeutics (TGTX) Misses Q2 EPS by 10c
August 1, 2023 7:22 AM
TG Therapeutics (TGTX) and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI
August 1, 2023 7:20 AM
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 1, 2023 7:15 AM
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
August 1, 2023 7:00 AM
